Literature DB >> 11888931

Allelic imbalance of 7q32.3-q36.1 during tumorigenesis in Barrett's esophagus.

Peter H J Riegman1, Lawrence J Burgart, Kenneth K Wang, Josiane C J Wink-Godschalk, Winand N M Dinjens, Peter D Siersema, Hugo W Tilanus, Herman van Dekken.   

Abstract

Malignant transformation of Barrett's esophagus is characterized by three distinct premalignant stages: intestinal metaplasia (MET), low- (LGD), and high-grade dysplasia (HGD). We reported recently an increase in the frequency of loss of 7q33-q35 between LGD and HGD as determined by comparative genomic hybridization (P. H. J. Riegman et al., Cancer Res., 61: 3164-3170, 2001). Now the 7q32.3-q36.1 region was additionally characterized by allelotype analysis with 11 polymorphic markers in 15 METs, 20 LGDs, 20 HGDs, and 20 Barrett's adenocarcinomas from different patients. Low percentages of imbalance were determined in METs and LGDs, 7% and 10%, respectively, whereas HGDs and Barrett's adenocarcinomas revealed high percentages of loss, 75% and 65%, respectively. This difference in frequency between LGDs and HGDs appeared highly significant: P = 0.00007. The majority of imbalances were found at D7S2439 and D7S483, located on 7q36.1. These data suggest that markers from this area can be used as a diagnostic tool in Barrett's esophagus, i.e., to distinguish between watchful waiting and active treatment.

Entities:  

Mesh:

Year:  2002        PMID: 11888931

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  5 in total

1.  The development of a fluorescence in situ hybridization assay for the detection of dysplasia and adenocarcinoma in Barrett's esophagus.

Authors:  Shannon M Brankley; Kenneth K Wang; Aaron R Harwood; Dylan V Miller; Mona S Legator; Lori S Lutzke; Benjamin R Kipp; Larry E Morrison; Kevin C Halling
Journal:  J Mol Diagn       Date:  2006-05       Impact factor: 5.568

2.  A comparison of conventional cytology, DNA ploidy analysis, and fluorescence in situ hybridization for the detection of dysplasia and adenocarcinoma in patients with Barrett's esophagus.

Authors:  Emily G Barr Fritcher; Shannon M Brankley; Benjamin R Kipp; Jesse S Voss; Michael B Campion; Larry E Morrison; Mona S Legator; Lori S Lutzke; Kenneth K Wang; Thomas J Sebo; Kevin C Halling
Journal:  Hum Pathol       Date:  2008-07-07       Impact factor: 3.466

3.  Methylation of TMEM176A is an independent prognostic marker and is involved in human colorectal cancer development.

Authors:  Dan Gao; Yingjie Han; Yang Yang; James G Herman; Enqiang Linghu; Qimin Zhan; François Fuks; Zhi John Lu; Mingzhou Guo
Journal:  Epigenetics       Date:  2017-07-05       Impact factor: 4.528

4.  Epigenetic silencing of TMEM176A activates ERK signaling in human hepatocellular carcinoma.

Authors:  Hongxia Li; Meiying Zhang; Enqiang Linghu; Fuyou Zhou; James G Herman; Liming Hu; Mingzhou Guo
Journal:  Clin Epigenetics       Date:  2018-11-06       Impact factor: 6.551

5.  Epigenetic silencing of TMEM176A promotes esophageal squamous cell cancer development.

Authors:  Ying Wang; You Zhang; James G Herman; Enqiang Linghu; Mingzhou Guo
Journal:  Oncotarget       Date:  2017-07-25
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.